참고문헌 (45)

1. 1. Hundal R Shaffer EA Gallbladder cancer: epidemiology and outcome Clin Epidemiol 2014 6 99 109 24634588 

2. 2. Lazcano-Ponce EC Miquel JF Munoz N Herrero R Ferrecio C Wistuba II Epidemiology and molecular pathology of gallbladder cancer CA Cancer J Clin 2001 51 349 64 11760569 

3. 3. Sheth S Bedford A Chopra S Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy Am J Gastroenterol 2000 95 1402 10 10894571 

   상세보기

4. 4. Andre T Tournigand C Rosmorduc O Provent S Maindrault-Goebel F Avenin D Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study Ann Oncol 2004 15 1339 43 15319238 

   상세보기

5. 5. Gruenberger B Schueller J Heubrandtner U Wrba F Tamandl D Kaczirek K Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study Lancet Oncol 2010 11 1142 48 21071270 

   상세보기

6. 6. Harder J Riecken B Kummer O Lohrmann C Otto F Usadel H Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer Br J Cancer 2006 95 848 52 16969352 

   상세보기

7. 7. Valle J Wasan H Palmer DH Cunningham D Anthoney A Maraveyas A Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N. Engl J Med 2010 362 1273 81 20375404 

   상세보기

8. 8. Lee J Park SH Chang HM Kim JS Choi HJ Lee MA Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study Lancet Oncol 2012 13 181 8 22192731 

   상세보기

9. 9. Malka D Cervera P Foulon S Trarbach T de la Fouchardiere C Boucher E Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial Lancet Oncol 2014 15 819 28 24852116 

   상세보기

10. 10. Dunn EF Iida M Myers RA Campbell DA Hintz KA Armstrong EA Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab Oncogene 2011 30 561 74 20956938 

    상세보기

11. 11. Bass-Zubek AE Hobbs RP Amargo EV Garcia NJ Hsieh SN Chen X Plakophilin 2: a critical scaffold for PKC alpha that regulates intercellular junction assembly J Cell Biol 2008 181 605 13 18474624 

12. 12. Nekrasova OE Amargo EV Smith WO Chen J Kreitzer GE Green KJ Desmosomal cadherins utilize distinct kinesins for assembly into desmosomes J Cell Biol 2011 195 1185 203 22184201 

    상세보기

13. 13. Takeichi M Dynamic contacts: rearranging adherens junctions to drive epithelial remodelling Nat Rev Mol Cell Biol 2014 15 397 410 24824068 

    상세보기

14. 14. Overmiller AM McGuinn KP Roberts BJ Cooper F Brennan-Crispi DM Deguchi T c-Src/Cav1-dependent activation of the EGFR by Dsg2 Oncotarget 2016 7 37536 55 26918609 

    상세보기

15. 15. Teh MT Parkinson EK Thurlow JK Liu F Fortune F Wan H A molecular study of desmosomes identifies a desmoglein isoform switch in head and neck squamous cell carcinoma J Oral Pathol Med 2011 40 67 76 20923451 

    상세보기

16. 16. Hutz K Zeiler J Sachs L Ormanns S Spindler V Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells Mol Carcinog 2017 56 1884 95 28277619 

    상세보기

17. 17. Peitsch WK Doerflinger Y Fischer-Colbrie R Huck V Bauer AT Utikal J Desmoglein 2 depletion leads to increased migration and upregulation of the chemoattractant secretoneurin in melanoma cells PloS One 2014 9 e89491 24558503 

    상세보기

18. 18. Yashiro M Nishioka N Hirakawa K Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma Eur J Cancer 2006 42 2397 403 16890424 

    상세보기

19. 19. Sirvent A Urbach S Roche S Contribution of phosphoproteomics in understanding SRC signaling in normal and tumor cells Proteomics 2015 15 232 44 25403792 

    상세보기

20. 20. Ishizawar R Parsons SJ c-Src and cooperating partners in human cancer Cancer Cell 2004 6 209 14 15380511 

    상세보기

21. 21. Pongchairerk U Guan JL Leardkamolkarn V Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line HuCCA-1 World J Gastroenterol 2005 11 5845 52 16270396 

    상세보기

22. 22. Biscardi JS Ishizawar RC Silva CM Parsons SJ Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer Breast Cancer Res 2000 2 203 10 11250711 

23. 23. Irby RB Mao W Coppola D Kang J Loubeau JM Trudeau W Activating SRC mutation in a subset of advanced human colon cancers Nat Genet 1999 21 187 90 9988270 

    상세보기

24. 24. Laghi L Bianchi P Orbetegli O Gennari L Roncalli M Malesci A Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients Br J Cancer 2001 84 196 8 11161376 

    상세보기

25. 25. Nilbert M Fernebro E Lack of activating c-SRC mutations at codon 531 in rectal cancer Cancer Genet Cytogenet 2000 121 94 5 10958949 

    상세보기

26. 26. Sugimura M Kobayashi K Sagae S Nishioka Y Ishioka S Terasawa K Mutation of the SRC gene in endometrial carcinoma Jpn J Cancer Res 2000 91 395 8 10804287 

27. 27. Wang NM Yeh KT Tsai CH Chen SJ Chang JG No evidence of correlation between mutation at codon 531 of src and the risk of colon cancer in Chinese Cancer Lett 2000 150 201 4 10704743 

    상세보기

28. 28. Ahn JY Lee JS Min HY Lee HY Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer Oncotarget 2015 6 32622 33 26416450 

    상세보기

29. 29. Tan Q Wang H Hu Y Hu M Li X Aodengqimuge Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy Cancer Sci 2015 106 1023 32 26041409 

    상세보기

30. 30. Zhang K Wang X Wang H Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line Mol Med Rep 2014 10 2065 72 25109654 

31. 31. Getsios S Simpson CL Kojima S Harmon R Sheu LJ Dusek RL Desmoglein 1-dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis J Cell Biol 2009 185 1243 58 19546243 

    상세보기

32. 32. Kamekura R Kolegraff KN Nava P Hilgarth RS Feng M Parkos CA Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling Oncogene 2014 33 4531 6 24166502 

    상세보기

33. 33. Klessner JL Desai BV Amargo EV Getsios S Green KJ EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2 Mol Biol Cell 2009 20 328 37 18987342 

    상세보기

34. 34. Chong CR Janne PA The quest to overcome resistance to EGFR-targeted therapies in cancer Nat Med 2013 19 1389 400 24202392 

    상세보기

35. 35. Barber AG Castillo-Martin M Bonal DM Rybicki BA Christiano AM Cordon-Cardo C Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer PloS One 2014 9 e98786 24896103 

    상세보기

36. 36. Overmiller AM Pierluissi JA Wermuth PJ Sauma S Martinez-Outschoorn U Tuluc M Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes FASEB J 2017 31 3412 24 28438789 

    상세보기

37. 37. Li M Chen W Zhang H Zhang Y Ke F Wu X MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer Oncotarget 2016 7 83060 70 27825112 

    상세보기

38. 38. Qin B Ariyama H Baba E Tanaka R Kusaba H Harada M Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells Cancer Chemother Pharm 2006 58 577 84 

39. 39. Stabile LP He G Lui VW Thomas S Henry C Gubish CT c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met Clin Cancer Res 2013 19 380 92 23213056 

    상세보기

40. 40. Wheeler DL Iida M Dunn EF The role of Src in solid tumors Oncologist 2009 14 667 78 19581523 

    상세보기

41. 41. Cavalloni G Peraldo-Neia C Sarotto I Gammaitoni L Migliardi G Soster M Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas Mol Cancer Ther 2012 11 1528 38 22452946 

    상세보기

42. 42. Lieu C Kopetz S The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy Clin Colorectal Cancer 2010 9 89 94 20378502 

    상세보기

43. 43. Lu Y Li X Liang K Luwor R Siddik ZH Mills GB Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab Cancer Res 2007 67 8240 7 17804738 

    상세보기

44. 44. Nam AR Kim JW Park JE Bang JH Jin MH Lee KH Src as a therapeutic target in biliary tract cancer Mol Cancer Ther 2016 15 1515 24 27196758 

    상세보기

45. 45. Zhang S Huang WC Zhang L Zhang C Lowery FJ Ding Z SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases Cancer Res 2013 73 5764 74 23913825 

    상세보기

활용도 Top5 논문

더보기

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.